mFOLFOX6与FOLFOX4化疗方案治疗直肠癌的临床疗效及安全性分析  

Clinical efficacy and safety analysis of mFOLFOX6 and FOLFOX4 chemotherapy regimens in the treatment of rectal cancer

作　　者：董骏 吴芳芳 Dong Jun;Wu Fangfang(Xuancheng Central Hospital,Xuancheng 242000,China)

机构地区：[1]宣城市中心医院肿瘤科,安徽省242000

出　　处：《中华消化病与影像杂志（电子版）》2023年第4期236-240,共5页Chinese Journal of Digestion and Medical Imageology(Electronic Edition)

摘　　要：目的分析比较两种化疗方案mFOLFOX6与FOLFOX4治疗直肠癌患者的临床疗效及安全性。方法选取2020年1月1日至2022年8月31日宣城市中心医院收治的118例直肠癌患者,按照随机字母表法将患者分为mFOLFOX6组(n=59)和FOLFOX4组(n=59),分别使用相应化疗方案进行治疗。比较两组治疗疗效及不良反应发生率。结果治疗后,mFOLFOX6组与FOLFOX4组临床客观缓解率和病情控制率无明显差异(P>0.05)。流式细胞仪检测显示治疗后mFOLFOX6组外周血CD3+细胞亚群较FOLFOX4组无明显差异(P>0.05),但CD4+细胞亚群及CD4+/CD8+明显高于FOLFOX4组(P<0.05)。生命质量方面,mFOLFOX6及FOLFOX4方案在治疗后的总体健康状况较治疗前均有改善(P<0.05),mFOLFOX6组功能量表评分和总体生存质量评分均明显高于FOLFOX4组,症状量表评分明显低于FOLFOX4组(P<0.05)。两组恶心呕吐、腹泻及外周神经毒性发生率无明显差异(P>0.05);mFOLFOX6组Ⅲ~Ⅳ度白细胞减少发生率均略高于FOLFOX4组,但差异无统计学意义(P>0.05);mFOLFOX6组肝损害发生率明显高于FOLFOX4组,差异有统计学意义(P<0.05)。结论mFOLFOX6与FOLFOX4方案在直肠癌的治疗中均能发挥较好的疗效,mFOLFOX6方案能较好的改善患者的生活质量及免疫功能,但肝损害发生率较高,肝功能不全患者应谨慎使用。Objective To analyze and compare the clinical efficacy and safety of mFOLFOX6 and FOLFOX4 chemotherapy regimens in the treatment of rectal cancer patients.Methods A total of 118 patients with rectal cancer who were admitted to Xuancheng Central Hospital from January 1,2020 to August 31,2022 were selected,and were divided into mFOLFOX6 group(n=59)and FOLFOX4 group(n=59)using random alphabet method.The patients were treated with mFOLFOX6 and FOLFOX4 chemotherapy regimens,respectively.The efficacy and incidence of adverse reactions were compared between the two groups.Results There were no significant differences in objective response rate and disease control rate between the mFOLFOX6 group and FOLFOX4 group(P>0.05).The results of flow cytometry showed that there was no significant difference in CD3+cell subset between the mFOLFOX6 group and FOLFOX4 group after treatment(P>0.05),while CD4+cell subset and CD4+/CD8+ratio in the mFOLFOX6 group were significantly higher than those in the FOLFOX4 group(P<0.05).In terms of quality of life,global health status was improved in both mFOLFOX6 and FOLFOX4 groups after treatment(P<0.05).The scores of functional scale and overall quality of life in the mFOLFOX6 group were significantly higher than those in the FOLFOX4 group,while the score of symptom scale was significantly lower than that in the FOLFOX4 group(P<0.05).The incidences of adverse reactions including nausea and vomiting,diarrhea and peripheral neurotoxicity were similar between the two groups(P>0.05).The incidence ofⅢ-Ⅳleukopenia in the mFOLFOX6 group was slightly higher than that in the FOLFOX4 group,but there was no statistically significant difference(P>0.05).The incidence of liver function damage in the mFOLFOX6 group was significantly higher than that in the FOLFOX4 group,and there was a statistically significant difference(P<0.05).Conclusion Both mFOLFOX6 and FOLFOX4 regimen can play a good role in the treatment of rectal cancer,and mFOLFOX6 regimen can improve the quality of life and immune function of pa

关 键 词：直肠癌 临床疗效 不良反应 MFOLFOX6 FOLFOX4 

分 类 号：R735.37[医药卫生—肿瘤]